JPWO2020104456A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020104456A5 JPWO2020104456A5 JP2021527887A JP2021527887A JPWO2020104456A5 JP WO2020104456 A5 JPWO2020104456 A5 JP WO2020104456A5 JP 2021527887 A JP2021527887 A JP 2021527887A JP 2021527887 A JP2021527887 A JP 2021527887A JP WO2020104456 A5 JPWO2020104456 A5 JP WO2020104456A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- optionally substituted
- aryl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 90
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 229910052799 carbon Inorganic materials 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 31
- 201000010099 disease Diseases 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000005842 heteroatoms Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 150000003536 tetrazoles Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 9
- 125000005549 heteroarylene group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- 210000004185 Liver Anatomy 0.000 claims 7
- 125000000732 arylene group Chemical group 0.000 claims 7
- 230000001684 chronic Effects 0.000 claims 7
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims 6
- 206010008635 Cholestasis Diseases 0.000 claims 6
- 208000008466 Metabolic Disease Diseases 0.000 claims 6
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 6
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 6
- 231100000359 cholestasis Toxicity 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 206010038428 Renal disease Diseases 0.000 claims 5
- 200000000018 inflammatory disease Diseases 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 4
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 4
- 102100009546 CYP27A1 Human genes 0.000 claims 4
- 101710036518 CYP27A1 Proteins 0.000 claims 4
- 208000001088 Cerebrotendinous Xanthomatosis Diseases 0.000 claims 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 4
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims 4
- 229950006238 nadide Drugs 0.000 claims 4
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 4
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 208000003269 Mitochondrial Disease Diseases 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004065 mitochondrial dysfunctions Effects 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010001627 Alcoholic liver disease Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010004637 Bile duct stone Diseases 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010018048 Gaucher's disease Diseases 0.000 claims 2
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010018704 Granulomatous liver disease Diseases 0.000 claims 2
- 206010018872 Haemochromatosis Diseases 0.000 claims 2
- 208000006454 Hepatitis Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001024 Intrahepatic Cholestasis Diseases 0.000 claims 2
- 206010029151 Nephropathy Diseases 0.000 claims 2
- 206010038436 Renal failure acute Diseases 0.000 claims 2
- 206010038444 Renal failure chronic Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 201000001203 Wilson disease Diseases 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 230000001580 bacterial Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000009331 choledocholithiasis Diseases 0.000 claims 2
- 201000000522 chronic kidney disease Diseases 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000009673 liver disease Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 208000001252 Hyperlipoproteinemias Diseases 0.000 claims 1
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 206010023379 Ketoacidosis Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034636 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001880 sexual dysfunction Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000001732 thrombotic Effects 0.000 claims 1
Claims (35)
Xが、H、S、SR2、NR2、NR2R2’、O、OH、ORh、F、Br、またはClであり、
Wが、NまたはCであり、
(i)WがNである場合、Lが、-(C(R5)2)mCH=CH(C(R5)2)p-、
(ii)WがCである場合、Lが、-(C(R5)2)mCH=CH(C(R5)2)p-、-(C(R5)2)o-、-(C(R5)2)mY1(C(R5)2)p-、
Y1が、O、NR4、またはS(O)qであり、
Y2が各々独立して、O、NH、またはSであり、
R1が、不在、C6-C10アリーレン、ヘテロアリーレン、またはC3-C8シクロアルキレンであり、前記ヘテロアリーレンが、1つまたは2つの5~7員環と、N、O、およびSから選択される1~4個のヘテロ原子とを含み、前記C6-C10アリーレン、前記ヘテロアリーレン、および前記C3-C8シクロアルキレンが、1~2つのReで任意に置換され、
R2が、HまたはC1-C4アルキルであり、
R2’が、H、C1-C4アルキル、またはC3-C7シクロアルキルであるか、または
R2とR2’が、それらが結合している窒素原子と一緒になって、N、O、およびSから選択される1~3個の追加のヘテロ原子を含む3~7員ヘテロシクロアルキル環を形成し、
R3が、HまたはC1-C4アルキルであり、
R4が、HまたはC1-C4アルキルであり、
R5が各々独立して、各出現時に、HまたはC1-C4アルキルであり、
R6が各々独立して、各出現時に、HまたはC1-C4アルキルであり、
R7が、H、A、B、またはCであり、
Aが、-(C(R6)2)rCO2Rx、-Y2(C(R6)2)rCO2Rx、-(C(R6)2)rテトラゾール、-(C(R6)2)rオキサジアゾロン、-(C(R6)2)rテトラゾロン、-(C(R6)2)rチアジアゾロール、-(C(R6)2)rイソオキサゾール-3-オール、-(C(R6)2)rP(O)(OH)ORx、-(C(R6)2)rS(O)2OH、-(C(R6)2)rC(O)NHCN、または-(C(R6)2)rC(O)NHS(O)2アルキルであり、-(C(R6)2)rテトラゾール、-(C(R6)2)rオキサジアゾロン、-(C(R6)2)rテトラゾロン、-(C(R6)2)rチアジアゾロール、-(C(R6)2)rイソオキサゾール-3-オールが、C1-C6アルキルで任意に置換され、
Bが、-(C(R6)2)rS(O)2OC1-C4アルキル、-O(C(R6)2)rS(O)2OC1-C4アルキル、-Y2(C(R6)2)rC(O)NRgRg’、-Y2(C(R6)2)rS(O)2NRgRg’、-(C(R6)2)rC(O)NRgRg’、-(C(R6)2)rS(O)2NRgRg’、-(C(R6)2)rC(O)NHS(O)2NRgRg’、-(C(R6)2)rCO2Ri、-(C(R6)2)rNH2CO2Rx、-(C(R6)2)rP(O)(ORx)2、-O(C(R6)2)rP(O)(ORx)2、-(C(R6)2)rS(O)2OH、-O(C(R6)2)rS(O)2OH、-(C(R6)2)rP(O)2ORx、または-O(C(R6)2)rP(O)2ORxであり、
Cが、-(CH2)rCN、-(CH2)sOH、ハロゲン、-(C(R6)2)rC6-C10アリール、-(C(R6)2)rS-C6-C10アリール、-(C(R6)2)rヘテロアリール、-O(C(R6)2)rヘテロアリール、-O(C(R6)2)rヘテロシクロアルキル、-O(C(R6)2)rOH、-ORy、-(C(R6)2)rC(O)NHCN、-CH=CHCO2Rx、または-(C(R6)2)rC(O)NHS(O)2C1-C4アルキルであり、前記アリールおよび前記ヘテロアリールが、各々C1-C6アルキル、C1-C6ハロアルキル、ハロゲン、およびOHから独立して選択される1~3つの置換基で置換され、前記ヘテロシクロアルキルが、1~2つの=Oまたは=Sで置換され、
Rcが、H、C1-C6アルキル、C1-C6ハロアルキル、ハロゲン、-CN、-ORx、または-CO2Rxであり、
Rdが、メチル、CF3、CRfF2、-(C(R6)2)tC6-C10アリール、-(C(R6)2)t-5員もしくは6員ヘテロアリール、-(C(R6)2)t-5員もしくは6員シクロアルキル、任意に置換されたC6-C10アリール、任意に置換された5員もしくは6員ヘテロアリール、または任意に置換された5員もしくは6員シクロアルキルであり、
Reが各々独立して、各出現時に、C1-C6アルキル、C2-C6アルケニル、C2-C6アルキニル、ハロゲン、C1-C6ハロアルキル、-NHRz、-OH、または-CNであり、
Rfが、不在、H、またはメチルであり、
Rgが、H、C1-C6アルキル、OH、-S(O)2(C1-C6アルキル)、またはS(O)2N(C1-C6アルキル)2であり、
Rg’が、H、C1-C6アルキル、C3-C7シクロアルキル、N、O、およびSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキル環、C6-C10アリール、またはN、O、およびSから選択される1~3個のヘテロ原子を含む5~7員ヘテロアリールであり、前記アルキルが、ハロゲンおよび-OHから独立して選択される1つ以上の置換基で任意に置換され、前記シクロアルキル、前記ヘテロシクロアルキル、前記アリール、および前記ヘテロアリールが、C1-C6アルキル、ハロゲン、および-OHから独立して選択される1つ以上の置換基で任意に置換され、
Rhが、H、C1-C4アルキル、またはN、O、およびSから選択される1~3個のヘテロ原子を含む3~7員ヘテロシクロアルキル環であり、前記アルキルが、各々NH2、C1-C4アルキルアミノ、C1-C4ジアルキルアミノ、およびC(O)NH2から独立して選択される1つ以上の置換基で任意に置換され、前記ヘテロシクロアルキルが、各々C1-C6アルキルおよびC1-C6ハロアルキルから独立して選択される1つ以上の置換基で任意に置換され、
Riが、(i)-(CH2)sOC(O)C1-C6アルキル(前記アルキルが1つ以上のNH2で置換される)、(ii)(CH2CH2O)nCH2CH2OH、または(iii)各々OH、およびO、N、またはSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキルから独立して選択される1つ以上の置換基で置換されたC1-C6アルキルであり、
Rjが、不在、H、C1-C6アルキル、または-CNであり、
Rxが各々独立して、各出現時に、H、C1-C6アルキル、またはC6-C10アリールであり、
RyおよびRzが各々独立して、H、C1-C6アルキル、またはC1-C6ハロアルキルであり、
m、p、q、r、およびtが各々独立して、0、1、または2であり、
nが、0、1、2、または3であり、
sが、1または2であり、
oが、0、1、2、3、または4であり、
但し、
XがOであり、RfがHであり、WがCであり、Rjが-CNであり、Lが-SCH2-であり、R1がフェニレンまたはピリジンである場合、R7が-COOHではなく、
XがOであり、RfがHであり、WがCであり、Rjが-CNであり、Lが-SCH2-であり、R1がフェニレンまたはピリジンであり、かつR7がテトラゾールである場合、RcがHではなく、
XがOであり、RfがHであり、WがCであり、Rjが-CNであり、Lが-S-C(R5)2または-SCH2CH2-であり、R1が不在である場合、R7がCOOHまたはテトラゾールではなく、
XがOであり、RfがHであり、WがNであり、Rjが不在であり、Rdが、メチル、任意に置換された5~10員アリール、任意に置換された5員もしくは6員ヘテロアリール、または任意に置換された5員もしくは6員シクロアルキルであり、Lが-SCH2-または-OCH2-であり、かつR1がフェニレンである場合、R7が、-COOH、-CH2COOH、
XがOであり、RfがHであり、WがNであり、Rjが不在であり、Lが、-NHCH2-、-CH2NH-、または-NH-C(O)-であり、かつR1がフェニレンである場合、Rdがフェニルではない、化合物、またはその薬学的に許容される塩もしくは互変異性体。 A compound represented by formula (II),
X is H, S, SR2 , NR2 , NR2R2 ' , O, OH, ORh , F, Br, or Cl;
W is N or C;
(i) when W is N, L is -(C(R 5 ) 2 ) m CH=CH(C(R 5 ) 2 ) p -,
(ii) when W is C, L is -(C(R 5 ) 2 ) m CH=CH(C(R 5 ) 2 ) p -, -(C(R 5 ) 2 ) o -, - (C(R 5 ) 2 ) m Y 1 (C(R 5 ) 2 ) p -,
Y 1 is O, NR 4 , or S(O) q ;
each Y 2 is independently O, NH, or S;
R 1 is absent, C 6 -C 10 arylene, heteroarylene, or C 3 -C 8 cycloalkylene, said heteroarylene being one or two 5- to 7-membered rings and N, O, and S and 1 to 4 heteroatoms selected from, wherein said C 6 -C 10 arylene, said heteroarylene, and said C 3 -C 8 cycloalkylene are optionally substituted with 1 to 2 R e ,
R 2 is H or C 1 -C 4 alkyl;
R 2′ is H, C 1 -C 4 alkyl, or C 3 -C 7 cycloalkyl, or R 2 and R 2′ together with the nitrogen atom to which they are attached are N forming a 3-7 membered heterocycloalkyl ring containing 1-3 additional heteroatoms selected from , O, and S;
R 3 is H or C 1 -C 4 alkyl;
R 4 is H or C 1 -C 4 alkyl;
each R 5 is independently at each occurrence H or C 1 -C 4 alkyl;
each R 6 is independently at each occurrence H or C 1 -C 4 alkyl;
R7 is H, A, B, or C;
A is —(C(R 6 ) 2 ) r CO 2 R x , —Y 2 (C(R 6 ) 2 ) r CO 2 R x , —(C(R 6 ) 2 ) r tetrazole, —(C (R 6 ) 2 ) r oxadiazolone, -(C(R 6 ) 2 ) r tetrazolone, -(C(R 6 ) 2 ) r thiadiazolol, -(C(R 6 ) 2 ) r isoxazole- 3-ol, —(C(R 6 ) 2 ) r P(O)(OH)OR x , —(C(R 6 ) 2 ) r S(O) 2 OH, —(C(R 6 ) 2 ) r C(O)NHCN, or —(C(R 6 ) 2 ) r C(O)NHS(O) 2 alkyl, —(C(R 6 ) 2 ) r tetrazole, —(C(R 6 ) 2 ) r oxadiazolone, -(C(R 6 ) 2 ) r tetrazolone, -(C(R 6 ) 2 ) r thiadiazolol, -(C(R 6 ) 2 ) r isoxazol-3-ol , optionally substituted with C 1 -C 6 alkyl,
B is —(C(R 6 ) 2 ) r S(O) 2 OC 1 -C 4 alkyl, —O(C(R 6 ) 2 ) r S(O) 2 OC 1 -C 4 alkyl, —Y 2 (C(R 6 ) 2 ) r C(O)NR g R g′ , —Y 2 (C(R 6 ) 2 ) r S(O) 2 NR g R g′ , —(C(R 6 ) 2 ) r C(O)NR g R g′ , —(C(R 6 ) 2 ) r S(O) 2 NR g R g′ , —(C(R 6 ) 2 ) r C(O)NHS( O) 2 NR g R g′ , —(C(R 6 ) 2 ) r CO 2 R i , —(C(R 6 ) 2 ) r NH 2 CO 2 R x , —(C(R 6 ) 2 ) r P(O)(OR x ) 2 , —O(C(R 6 ) 2 ) r P(O)(OR x ) 2 , —(C(R 6 ) 2 ) r S(O) 2 OH, — O(C(R 6 ) 2 ) r S(O) 2 OH, —(C(R 6 ) 2 ) r P(O) 2 OR x , or —O(C(R 6 ) 2 ) r P(O ) 2 OR x , and
C is —(CH 2 ) r CN, —(CH 2 ) s OH, halogen, —(C(R 6 ) 2 ) r C 6 —C 10 aryl, —(C(R 6 ) 2 ) r S— C 6 -C 10 aryl, —(C(R 6 ) 2 ) r heteroaryl, —O(C(R 6 ) 2 ) r heteroaryl, —O(C(R 6 ) 2 ) r heterocycloalkyl, — O(C(R 6 ) 2 ) r OH, —OR y , —(C(R 6 ) 2 ) r C(O)NHCN, —CH═CHCO 2 R x , or —(C(R 6 ) 2 ) r C(O)NHS(O) 2 C 1 -C 4 alkyl, wherein said aryl and said heteroaryl are each independently from C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, and OH substituted with 1-3 selected substituents, said heterocycloalkyl is substituted with 1-2 ═O or ═S;
R c is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, —CN, —OR x , or —CO 2 R x ;
R d is methyl, CF 3 , CR f F 2 , —(C(R 6 ) 2 ) t C 6 -C 10 aryl, —(C(R 6 ) 2 ) t -5- or 6-membered heteroaryl; —(C(R 6 ) 2 ) t —5- or 6-membered cycloalkyl, optionally substituted C 6 -C 10 aryl, optionally substituted 5- or 6-membered heteroaryl, or optionally substituted 5- or 6-membered cycloalkyl,
each R e is independently at each occurrence C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, C 1 -C 6 haloalkyl, —NHR z , —OH, or -CN;
R f is absent, H, or methyl;
R g is H, C 1 -C 6 alkyl, OH, —S(O) 2 (C 1 -C 6 alkyl), or S(O) 2 N(C 1 -C 6 alkyl) 2 ,
a 4- to 7-membered heterocycloalkyl ring in which R g′ contains 1-3 heteroatoms selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, N, O, and S; C 6 -C 10 aryl or 5-7 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is independently selected from halogen and —OH wherein said cycloalkyl, said heterocycloalkyl, said aryl, and said heteroaryl are independently selected from C 1 -C 6 alkyl, halogen, and —OH optionally substituted with one or more substituents;
R h is H, C 1 -C 4 alkyl, or a 3- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is each NH 2 , C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, and C(O)NH 2 optionally substituted with one or more substituents, wherein said heterocycloalkyl is optionally substituted with one or more substituents each independently selected from C 1 -C 6 alkyl and C 1 -C 6 haloalkyl;
R i is (i) —(CH 2 ) s OC(O)C 1 -C 6 alkyl, wherein said alkyl is substituted with one or more NH 2 , (ii) (CH 2 CH 2 O) n CH 2 CH 2 OH, or (iii) each OH and one or more independently selected from 4-7 membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, or S C 1 -C 6 alkyl substituted with a substituent of
R j is absent, H, C 1 -C 6 alkyl, or —CN;
each R x is independently, at each occurrence, H, C 1 -C 6 alkyl, or C 6 -C 10 aryl;
R y and R z are each independently H, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;
m, p, q, r, and t are each independently 0, 1, or 2;
n is 0, 1, 2, or 3;
s is 1 or 2,
o is 0, 1, 2, 3, or 4;
however,
When X is O, R f is H, W is C, R j is —CN, L is —SCH 2 — and R 1 is phenylene or pyridine, then R 7 is — COOH, not
X is O, R f is H, W is C, R j is —CN, L is —SCH 2 —, R 1 is phenylene or pyridine, and R 7 is tetrazole , then R c is not H and
X is O, R f is H, W is C, R j is —CN, L is —SC(R 5 ) 2 or —SCH 2 CH 2 —, and R 1 is absent, R7 is not COOH or tetrazole,
X is O, R f is H, W is N, R j is absent, R d is methyl, optionally substituted 5- to 10-membered aryl, optionally substituted 5-membered or 6-membered heteroaryl, or optionally substituted 5- or 6-membered cycloalkyl, when L is —SCH 2 — or —OCH 2 — and R 1 is phenylene, then R 7 is — COOH, -CH2COOH ,
X is O, R f is H, W is N, R j is absent, and L is —NHCH 2 —, —CH 2 NH—, or —NH—C(O)— and when R 1 is phenylene, then R d is not phenyl, or a pharmaceutically acceptable salt or tautomer thereof.
Xが、H、S、SRX is H, S, SR 22 、NR, NR 22 、NR, NR 22 RR. 2’2' 、O、OH、OR, O, OH, OR hh 、F、またはBrであり、, F, or Br;
Wが、NまたはCであり、W is N or C;
(i)WがNである場合、Lが、-(C(R(i) if W is N, then L is -(C(R 55 )) 22 )) mm CH=CH(C(RCH=CH(C(R 55 )) 22 )) pp -、-,
(ii)WがCである場合、Lが、-(C(R (ii) if W is C, then L is -(C(R 55 )) 22 )) mm CH=CH(C(RCH=CH(C(R 55 )) 22 )) pp -、-(C(R-, -(C(R 55 )) 22 )) oo -、-(C(R-, -(C(R 55 )) 22 )) mm YY. 11 (C(R(C(R 55 )) 22 )) pp -、-,
YY. 11 が、O、NRis O, NR 44 、またはS(O), or S(O) qq であり、and
YY. 22 が各々独立して、O、NH、またはSであり、are each independently O, NH, or S;
RR. 11 が、不在、Cis absent, C 66 -C-C 1010 アリーレン、ヘテロアリーレン、またはCarylene, heteroarylene, or C 33 -C-C 88 シクロアルキレンであり、前記ヘテロアリーレンが、1つまたは2つの5~7員環と、N、O、およびSから選択される1~4個のヘテロ原子とを含み、前記CC 66 -C-C 1010 アリーレン、前記ヘテロアリーレン、および前記Carylene, said heteroarylene, and said C 33 -C-C 88 シクロアルキレンが、1~2つのRcycloalkylene is 1 to 2 R ee で任意に置換され、is arbitrarily replaced by
RR. 22 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 2’2' が、H、Cbut H, C 11 -C-C 44 アルキル、またはCalkyl, or C 33 -C-C 77 シクロアルキルであるか、またはis cycloalkyl, or
RR. 22 とRand R 2’2' が、それらが結合している窒素原子と一緒になって、N、O、およびSから選択される1~3個の追加のヘテロ原子を含む3~7員ヘテロシクロアルキル環を形成し、together with the nitrogen atom to which they are attached form a 3- to 7-membered heterocycloalkyl ring containing 1-3 additional heteroatoms selected from N, O, and S;
RR. 33 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 44 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 55 が各々独立して、各出現時に、HまたはCeach independently, at each occurrence, H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 66 が各々独立して、各出現時に、HまたはCeach independently, at each occurrence, H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 77 が、H、A、B、またはCであり、is H, A, B, or C;
Aが、-(C(RA is -(C(R 66 )) 22 )) rr COCO 22 RR. xx 、-Y, -Y 22 (C(R(C(R 66 )) 22 )) rr COCO 22 RR. xx 、-(C(R,-(C(R 66 )) 22 )) rr テトラゾール、-(C(Rtetrazole, -(C(R 66 )) 22 )) rr オキサジアゾロン、-(C(ROxadiazolone, -(C(R 66 )) 22 )) rr テトラゾロン、-(C(Rtetrazolone, -(C(R 66 )) 22 )) rr チアジアゾロール、-(C(RThiadiazolol, -(C(R 66 )) 22 )) rr イソオキサゾール-3-オール、-(C(Risoxazol-3-ol, —(C(R 66 )) 22 )) rr P(O)(OH)ORP(O)(OH)OR xx 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-(C(ROH,-(C(R 66 )) 22 )) rr C(O)NHCN、または-(C(RC(O)NHCN, or -(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 アルキルであり、-(C(Ris alkyl and —(C(R 66 )) 22 )) rr テトラゾール、-(C(Rtetrazole, -(C(R 66 )) 22 )) rr オキサジアゾロン、-(C(ROxadiazolone, -(C(R 66 )) 22 )) rr テトラゾロン、-(C(Rtetrazolone, -(C(R 66 )) 22 )) rr チアジアゾロール、-(C(RThiadiazolol, -(C(R 66 )) 22 )) rr イソオキサゾール-3-オールが、CIsoxazol-3-ol is C 11 -C-C 66 アルキルで任意に置換され、optionally substituted with alkyl,
Bが、-(C(RB is -(C(R 66 )) 22 )) rr S(O)S(O) 22 OCOC 11 -C-C 44 アルキル、-O(C(Ralkyl, —O(C(R 66 )) 22 )) rr S(O)S(O) 22 OCOC 11 -C-C 44 アルキル、-Yalkyl, -Y 22 (C(R(C(R 66 )) 22 )) rr C(O)NRC(O)NR gg RR. g’g' 、-Y, -Y 22 (C(R(C(R 66 )) 22 )) rr S(O)S(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NRC(O)NR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr COCO 22 RR. ii 、-(C(R,-(C(R 66 )) 22 )) rr NHNH 22 COCO 22 RR. xx 、-(C(R,-(C(R 66 )) 22 )) rr P(O)(ORP(O)(OR xx )) 22 、-O(C(R, -O(C(R 66 )) 22 )) rr P(O)(ORP(O)(OR xx )) 22 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-O(C(ROH, —O(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-(C(ROH,-(C(R 66 )) 22 )) rr P(O)P(O) 22 OROR xx 、または-O(C(R, or -O(C(R 66 )) 22 )) rr P(O)P(O) 22 OROR xx であり、and
Cが、-(CHC is -(CH 22 )) rr CN、-(CHCN, -(CH 22 )) ss OH、ハロゲン、-(C(ROH, halogen, -(C(R 66 )) 22 )) rr CC. 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) rr S-CSC 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) rr ヘテロアリール、-O(C(Rheteroaryl, —O(C(R 66 )) 22 )) rr ヘテロアリール、-O(C(Rheteroaryl, —O(C(R 66 )) 22 )) rr ヘテロシクロアルキル、-O(C(Rheterocycloalkyl, —O(C(R 66 )) 22 )) rr OH、-OROH, -OR yy 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NHCN、-CH=CHCOC(O)NHCN, -CH=CHCO 22 RR. xx 、または-(C(R, or -(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 CC. 11 -C-C 44 アルキルであり、前記アリールおよび前記ヘテロアリールが、各々Calkyl, wherein said aryl and said heteroaryl are each C 11 -C-C 66 アルキル、Calkyl, C 11 -C-C 66 ハロアルキル、ハロゲン、およびOHから独立して選択される1~3つの置換基で置換され、前記ヘテロシクロアルキルが、1~2つの=Oまたは=Sで置換され、substituted with 1-3 substituents independently selected from haloalkyl, halogen, and OH, said heterocycloalkyl substituted with 1-2 ═O or ═S;
RR. cc が、H、Cbut H, C 11 -C-C 66 アルキル、Calkyl, C 11 -C-C 66 ハロアルキル、ハロゲン、-CN、-ORhaloalkyl, halogen, -CN, -OR xx 、または-CO, or -CO 22 RR. xx であり、and
RR. dd が、メチル、CFis methyl, CF 33 、CR, CR ff FF. 22 、-(C(R,-(C(R 66 )) 22 )) tt CC. 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) tt -5員もしくは6員ヘテロアリール、-(C(R-5- or 6-membered heteroaryl, -(C(R 66 )) 22 )) tt -5員もしくは6員シクロアルキル、任意に置換されたC-5- or 6-membered cycloalkyl, optionally substituted C 66 -C-C 1010 アリール、任意に置換された5員もしくは6員ヘテロアリール、または任意に置換された5員もしくは6員シクロアルキルであり、aryl, optionally substituted 5- or 6-membered heteroaryl, or optionally substituted 5- or 6-membered cycloalkyl;
RR. ee が各々独立して、各出現時に、Ceach independently, at each occurrence, C 11 -C-C 66 アルキル、Calkyl, C 22 -C-C 66 アルケニル、Calkenyl, C 22 -C-C 66 アルキニル、ハロゲン、Calkynyl, halogen, C 11 -C-C 66 ハロアルキル、-NHRhaloalkyl, —NHR zz 、-OH、または-CNであり、, —OH, or —CN;
RR. ff が、不在、H、またはメチルであり、is absent, H, or methyl;
RR. gg が、H、Cbut H, C 11 -C-C 66 アルキル、OH、-S(O)alkyl, OH, —S(O) 22 (C(C 11 -C-C 66 アルキル)、またはS(O)alkyl), or S(O) 22 N(CN(C 11 -C-C 66 アルキル)alkyl) 22 であり、and
RR. g’g' が、H、Cbut H, C 11 -C-C 66 アルキル、Calkyl, C 33 -C-C 77 シクロアルキル、N、O、およびSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキル環、C4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from cycloalkyl, N, O, and S, C 66 -C-C 1010 アリール、またはN、O、およびSから選択される1~3個のヘテロ原子を含む5~7員ヘテロアリールであり、前記アルキルが、ハロゲンおよび-OHから独立して選択される1つ以上の置換基で任意に置換され、前記シクロアルキル、前記ヘテロシクロアルキル、前記アリール、および前記ヘテロアリールが、Caryl or 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is one or more independently selected from halogen and —OH optionally substituted with substituents, wherein said cycloalkyl, said heterocycloalkyl, said aryl, and said heteroaryl are C 11 -C-C 66 アルキル、ハロゲン、および-OHから独立して選択される1つ以上の置換基で任意に置換され、optionally substituted with one or more substituents independently selected from alkyl, halogen, and —OH;
RR. hh が、H、Cbut H, C 11 -C-C 44 アルキル、またはN、O、およびSから選択される1~3個のヘテロ原子を含む3~7員ヘテロシクロアルキル環であり、前記アルキルが、各々NHalkyl or a 3- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is each NH 22 、C, C 11 -C-C 44 アルキルアミノ、Calkylamino, C 11 -C-C 44 ジアルキルアミノ、およびC(O)NHdialkylamino, and C(O)NH 22 から独立して選択される1つ以上の置換基で任意に置換され、前記ヘテロシクロアルキルが、各々Coptionally substituted with one or more substituents independently selected from, said heterocycloalkyl each being C 11 -C-C 66 アルキルおよびCalkyl and C 11 -C-C 66 ハロアルキルから独立して選択される1つ以上の置換基で任意に置換され、optionally substituted with one or more substituents independently selected from haloalkyl;
RR. ii が、(i)-(CHis (i)-(CH 22 )) ss OC(O)COC(O)C 11 -C-C 66 アルキル(前記アルキルが1つ以上のNHAlkyl, wherein said alkyl is one or more NH 22 で置換される)、(ii)(CH), (ii) (CH 22 CHCH 22 O)O) nn CHCH 22 CHCH 22 OH、または(iii)各々OH、およびO、N、またはSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキルから独立して選択される1つ以上の置換基で置換されたCOH, or (iii) each OH and one or more substituents independently selected from 4- to 7-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, or S permuted C 11 -C-C 66 アルキルであり、is an alkyl,
RR. jj が、不在、H、Cis absent, H, C 11 -C-C 66 アルキル、または-CNであり、alkyl, or -CN,
RR. xx が各々独立して、各出現時に、H、Care each independent, and at each occurrence, H, C 11 -C-C 66 アルキル、またはCalkyl, or C 66 -C-C 1010 アリールであり、is aryl,
RR. yy およびRand R zz が各々独立して、H、Care each independently H, C 11 -C-C 66 アルキル、またはCalkyl, or C 11 -C-C 66 ハロアルキルであり、is haloalkyl;
m、p、q、r、およびtが各々独立して、0、1、または2であり、m, p, q, r, and t are each independently 0, 1, or 2;
nが、0、1、2、または3であり、n is 0, 1, 2, or 3;
sが、1または2であり、s is 1 or 2,
oが、0、1、2、3、または4であり、o is 0, 1, 2, 3, or 4;
但し、however,
XがOであり、RX is O and R ff がHであり、WがCであり、Ris H, W is C, and R jj が-CNであり、Lが-SCHis -CN and L is -SCH 22 -であり、R- and R 11 がフェニレンまたはピリジンである場合、Ris phenylene or pyridine, then R 77 が-COOHではなく、is not -COOH,
XがOであり、RX is O and R ff がHであり、WがCであり、Ris H, W is C, and R jj が-CNであり、Lが-SCHis -CN and L is -SCH 22 -であり、R- and R 11 がフェニレンまたはピリジンであり、かつRis phenylene or pyridine, and R 77 がテトラゾールである場合、Ris tetrazole, then R cc がHではなく、is not H,
XがOであり、RX is O and R ff がHであり、WがCであり、Ris H, W is C, and R jj が-CNであり、Lが-S-C(Ris -CN, and L is -SC (R 55 )) 22 または-SCHor -SCH 22 CHCH 22 -であり、R- and R 11 が不在である場合、Ris absent, then R 77 がCOOHまたはテトラゾールではなく、is not COOH or tetrazole,
XがOであり、RX is O and R ff がHであり、WがNであり、Ris H, W is N, and R jj が不在であり、Ris absent and R dd が、メチル、任意に置換された5~10員アリール、任意に置換された5員もしくは6員ヘテロアリール、または任意に置換された5員もしくは6員シクロアルキルであり、Lが-SCHis methyl, optionally substituted 5- to 10-membered aryl, optionally substituted 5- or 6-membered heteroaryl, or optionally substituted 5- or 6-membered cycloalkyl, and L is —SCH 22 -または-OCH- or -OCH 22 -であり、かつR- and R 11 がフェニレンである場合、Ris phenylene, then R 77 が、-COOH、-CHis, -COOH, -CH 22 COOH、COOH,
XがOであり、RX is O and R ff がHであり、WがNであり、Ris H, W is N, and R jj が不在であり、Lが、-NHCHis absent and L is -NHCH 22 -、-CH-, -CH 22 NH-、または-NH-C(O)-であり、かつRNH—, or —NH—C(O)—, and R 11 がフェニレンである場合、Ris phenylene, then R dd がフェニルではない、請求項1に記載の化合物、またはその薬学的に許容される塩もしくは互変異性体。2. The compound of claim 1, or a pharmaceutically acceptable salt or tautomer thereof, wherein is not phenyl.
Xが、H、S、SRX is H, S, SR 22 、NR, NR 22 、NR, NR 22 RR. 2’2' 、O、OH、OR, O, OH, OR hh 、F、Br、またはClであり、, F, Br, or Cl;
Wが、Nであり、W is N,
Lが、-(C(RL is -(C(R 55 )) 22 )) mm YY. 11 (C(R(C(R 55 )) 22 )) pp -であり、- and
YY. 11 が、NRbut NR 44 であり、and
YY. 22 が各々独立して、O、NH、またはSであり、are each independently O, NH, or S;
RR. 11 が、不在、Cis absent, C 66 -C-C 1010 アリーレン、ヘテロアリーレン、またはCarylene, heteroarylene, or C 33 -C-C 88 シクロアルキレンであり、前記ヘテロアリーレンが、1つまたは2つの5~7員環と、N、O、およびSから選択される1~4個のヘテロ原子とを含み、前記CC 66 -C-C 1010 アリーレン、前記ヘテロアリーレン、および前記Carylene, said heteroarylene, and said C 33 -C-C 88 シクロアルキレンが、1~2つのRcycloalkylene is 1 to 2 R ee で任意に置換され、is arbitrarily replaced by
RR. 22 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 2’2' が、H、Cbut H, C 11 -C-C 44 アルキル、またはCalkyl, or C 33 -C-C 77 シクロアルキルであるか、またはis cycloalkyl, or
RR. 22 とRand R 2’2' が、それらが結合している窒素原子と一緒になって、N、O、およびSから選択される1~3個の追加のヘテロ原子を含む3~7員ヘテロシクロアルキル環を形成し、together with the nitrogen atom to which they are attached form a 3- to 7-membered heterocycloalkyl ring containing 1-3 additional heteroatoms selected from N, O, and S;
RR. 33 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 44 が、HまたはCis H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 55 が各々独立して、各出現時に、HまたはCeach independently, at each occurrence, H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 66 が各々独立して、各出現時に、HまたはCeach independently, at each occurrence, H or C 11 -C-C 44 アルキルであり、is an alkyl,
RR. 77 が、H、A、B、またはCであり、is H, A, B, or C;
Aが、-(C(RA is -(C(R 66 )) 22 )) rr COCO 22 RR. xx 、-Y, -Y 22 (C(R(C(R 66 )) 22 )) rr COCO 22 RR. xx 、-(C(R,-(C(R 66 )) 22 )) rr テトラゾール、-(C(Rtetrazole, -(C(R 66 )) 22 )) rr オキサジアゾロン、-(C(ROxadiazolone, -(C(R 66 )) 22 )) rr テトラゾロン、-(C(Rtetrazolone, -(C(R 66 )) 22 )) rr チアジアゾロール、-(C(RThiadiazolol, -(C(R 66 )) 22 )) rr イソオキサゾール-3-オール、-(C(Risoxazol-3-ol, —(C(R 66 )) 22 )) rr P(O)(OH)ORP(O)(OH)OR xx 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-(C(ROH,-(C(R 66 )) 22 )) rr C(O)NHCN、または-(C(RC(O)NHCN, or -(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 アルキルであり、-(C(Ris alkyl and —(C(R 66 )) 22 )) rr テトラゾール、-(C(Rtetrazole, -(C(R 66 )) 22 )) rr オキサジアゾロン、-(C(ROxadiazolone, -(C(R 66 )) 22 )) rr テトラゾロン、-(C(Rtetrazolone, -(C(R 66 )) 22 )) rr チアジアゾロール、-(C(RThiadiazolol, -(C(R 66 )) 22 )) rr イソオキサゾール-3-オールが、CIsoxazol-3-ol is C 11 -C-C 66 アルキルで任意に置換され、optionally substituted with alkyl,
Bが、-(C(RB is -(C(R 66 )) 22 )) rr S(O)S(O) 22 OCOC 11 -C-C 44 アルキル、-O(C(Ralkyl, —O(C(R 66 )) 22 )) rr S(O)S(O) 22 OCOC 11 -C-C 44 アルキル、-Yalkyl, -Y 22 (C(R(C(R 66 )) 22 )) rr C(O)NRC(O)NR gg RR. g’g' 、-Y, -Y 22 (C(R(C(R 66 )) 22 )) rr S(O)S(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NRC(O)NR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 NRNR gg RR. g’g' 、-(C(R,-(C(R 66 )) 22 )) rr COCO 22 RR. ii 、-(C(R,-(C(R 66 )) 22 )) rr NHNH 22 COCO 22 RR. xx 、-(C(R,-(C(R 66 )) 22 )) rr P(O)(ORP(O)(OR xx )) 22 、-O(C(R, -O(C(R 66 )) 22 )) rr P(O)(ORP(O)(OR xx )) 22 、-(C(R,-(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-O(C(ROH, —O(C(R 66 )) 22 )) rr S(O)S(O) 22 OH、-(C(ROH,-(C(R 66 )) 22 )) rr P(O)P(O) 22 OROR xx 、または-O(C(R, or -O(C(R 66 )) 22 )) rr P(O)P(O) 22 OROR xx であり、and
Cが、-(CHC is -(CH 22 )) rr CN、-(CHCN, -(CH 22 )) ss OH、ハロゲン、-(C(ROH, halogen, -(C(R 66 )) 22 )) rr CC. 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) rr S-CSC 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) rr ヘテロアリール、-O(C(Rheteroaryl, —O(C(R 66 )) 22 )) rr ヘテロアリール、-O(C(Rheteroaryl, —O(C(R 66 )) 22 )) rr ヘテロシクロアルキル、-O(C(Rheterocycloalkyl, —O(C(R 66 )) 22 )) rr OH、-OROH, -OR yy 、-(C(R,-(C(R 66 )) 22 )) rr C(O)NHCN、-CH=CHCOC(O)NHCN, -CH=CHCO 22 RR. xx 、または-(C(R, or -(C(R 66 )) 22 )) rr C(O)NHS(O)C(O)NHS(O) 22 CC. 11 -C-C 44 アルキルであり、前記アリールおよび前記ヘテロアリールが、各々Calkyl, wherein said aryl and said heteroaryl are each C 11 -C-C 66 アルキル、Calkyl, C 11 -C-C 66 ハロアルキル、ハロゲン、およびOHから独立して選択される1~3つの置換基で置換され、前記ヘテロシクロアルキルが、1~2つの=Oまたは=Sで置換され、substituted with 1 to 3 substituents independently selected from haloalkyl, halogen, and OH, wherein said heterocycloalkyl is substituted with 1 to 2 ═O or ═S;
RR. cc が、H、Cbut H, C 11 -C-C 66 アルキル、Calkyl, C 11 -C-C 66 ハロアルキル、ハロゲン、-CN、-ORhaloalkyl, halogen, -CN, -OR xx 、または-CO, or -CO 22 RR. xx であり、and
RR. dd が、メチル、CFis methyl, CF 33 、CR, CR ff FF. 22 、-(C(R,-(C(R 66 )) 22 )) tt CC. 66 -C-C 1010 アリール、-(C(RAryl, -(C(R 66 )) 22 )) tt -5員もしくは6員ヘテロアリール、-(C(R-5- or 6-membered heteroaryl, -(C(R 66 )) 22 )) tt -5員もしくは6員シクロアルキル、任意に置換されたC-5- or 6-membered cycloalkyl, optionally substituted C 66 -C-C 1010 アリール、任意に置換された5員もしくは6員ヘテロアリール、または任意に置換された5員もしくは6員シクロアルキルであり、aryl, optionally substituted 5- or 6-membered heteroaryl, or optionally substituted 5- or 6-membered cycloalkyl;
RR. ee が各々独立して、各出現時に、Ceach independently, at each occurrence, C 11 -C-C 66 アルキル、Calkyl, C 22 -C-C 66 アルケニル、Calkenyl, C 22 -C-C 66 アルキニル、ハロゲン、Calkynyl, halogen, C 11 -C-C 66 ハロアルキル、-NHRhaloalkyl, —NHR zz 、-OH、または-CNであり、, —OH, or —CN;
RR. ff が、不在、H、またはメチルであり、is absent, H, or methyl;
RR. gg が、H、Cbut H, C 11 -C-C 66 アルキル、OH、-S(O)alkyl, OH, —S(O) 22 (C(C 11 -C-C 66 アルキル)、またはS(O)alkyl), or S(O) 22 N(CN(C 11 -C-C 66 アルキル)alkyl) 22 であり、and
RR. g’g' が、H、Cbut H, C 11 -C-C 66 アルキル、Calkyl, C 33 -C-C 77 シクロアルキル、N、O、およびSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキル環、C4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from cycloalkyl, N, O, and S, C 66 -C-C 1010 アリール、またはN、O、およびSから選択される1~3個のヘテロ原子を含む5~7員ヘテロアリールであり、前記アルキルが、ハロゲンおよび-OHから独立して選択される1つ以上の置換基で任意に置換され、前記シクロアルキル、前記ヘテロシクロアルキル、前記アリール、および前記ヘテロアリールが、Caryl or 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is one or more independently selected from halogen and —OH optionally substituted with substituents, wherein said cycloalkyl, said heterocycloalkyl, said aryl, and said heteroaryl are C 11 -C-C 66 アルキル、ハロゲン、および-OHから独立して選択される1つ以上の置換基で任意に置換され、optionally substituted with one or more substituents independently selected from alkyl, halogen, and —OH;
RR. hh が、H、Cbut H, C 11 -C-C 44 アルキル、またはN、O、およびSから選択される1~3個のヘテロ原子を含む3~7員ヘテロシクロアルキル環であり、前記アルキルが、各々NHalkyl or a 3- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from N, O, and S, wherein said alkyl is each NH 22 、C, C 11 -C-C 44 アルキルアミノ、Calkylamino, C 11 -C-C 44 ジアルキルアミノ、およびC(O)NHdialkylamino, and C(O)NH 22 から独立して選択される1つ以上の置換基で任意に置換され、前記ヘテロシクロアルキルが、各々Coptionally substituted with one or more substituents independently selected from, said heterocycloalkyl each being C 11 -C-C 66 アルキルおよびCalkyl and C 11 -C-C 66 ハロアルキルから独立して選択される1つ以上の置換基で任意に置換され、optionally substituted with one or more substituents independently selected from haloalkyl;
RR. ii が、(i)-(CHis (i)-(CH 22 )) ss OC(O)COC(O)C 11 -C-C 66 アルキル(前記アルキルが1つ以上のNHAlkyl, wherein said alkyl is one or more NH 22 で置換される)、(ii)(CH), (ii) (CH 22 CHCH 22 O)O) nn CHCH 22 CHCH 22 OH、または(iii)各々OH、およびO、N、またはSから選択される1~3個のヘテロ原子を含む4~7員ヘテロシクロアルキルから独立して選択される1つ以上の置換基で置換されたCOH, or (iii) each OH and one or more substituents independently selected from 4- to 7-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, or S permuted C 11 -C-C 66 アルキルであり、is an alkyl,
RR. jj が、不在、H、Cis absent, H, C 11 -C-C 66 アルキル、または-CNであり、alkyl, or -CN,
RR. xx が各々独立して、各出現時に、H、Care each independent, and at each occurrence, H, C 11 -C-C 66 アルキル、またはCalkyl, or C 66 -C-C 1010 アリールであり、is aryl,
RR. yy およびRand R zz が各々独立して、H、Care each independently H, C 11 -C-C 66 アルキル、またはCalkyl, or C 11 -C-C 66 ハロアルキルであり、is haloalkyl;
m、p、q、r、およびtが各々独立して、0、1、または2であり、m, p, q, r, and t are each independently 0, 1, or 2;
nが、0、1、2、または3であり、n is 0, 1, 2, or 3;
sが、1または2であり、s is 1 or 2,
oが、0、1、2、3、または4であり、o is 0, 1, 2, 3, or 4;
但し、however,
XがOであり、RX is O and R ff がHであり、WがNであり、Ris H, W is N, and R jj が不在であり、Lが、-NHCHis absent and L is -NHCH 22 -、-CH-, -CH 22 NH-、または-NH-C(O)-であり、かつRNH—, or —NH—C(O)—, and R 11 がフェニレンである場合、Ris phenylene, then R dd がフェニルではない、請求項1に記載の化合物、またはその薬学的に許容される塩もしくは互変異性体。2. The compound of claim 1, or a pharmaceutically acceptable salt or tautomer thereof, wherein is not phenyl.
(a)O、OH、ORh、F、Br、またはCl;
(b)O、OH、OR h 、F、またはBr;
(c)H、S、SR 2 、NR 2 、またはNR 2 R 2’
である、請求項1~3のいずれか1項に記載の化合物。 X is
(a) O, OH, ORh , F, Br, or Cl ;
(b) O, OH, ORh , F, or Br;
( c) H, S, SR2 , NR2 , or NR2R2 '
The compound according to any one of claims 1 to 3, which is
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769959P | 2018-11-20 | 2018-11-20 | |
US62/769,959 | 2018-11-20 | ||
PCT/EP2019/081799 WO2020104456A1 (en) | 2018-11-20 | 2019-11-19 | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022507805A JP2022507805A (en) | 2022-01-18 |
JPWO2020104456A5 true JPWO2020104456A5 (en) | 2022-11-22 |
Family
ID=68696375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021527887A Pending JP2022507805A (en) | 2018-11-20 | 2019-11-19 | α-Amino-β-carboxymuconic acid semialdehyde decarboxylase inhibitor |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220354848A9 (en) |
EP (1) | EP3883930A1 (en) |
JP (1) | JP2022507805A (en) |
KR (1) | KR20210111248A (en) |
CN (1) | CN113302189A (en) |
AR (1) | AR117122A1 (en) |
AU (1) | AU2019385644A1 (en) |
BR (1) | BR112021009589A2 (en) |
CA (1) | CA3119509A1 (en) |
IL (1) | IL283182A (en) |
MX (1) | MX2021005904A (en) |
SG (1) | SG11202104550WA (en) |
TW (1) | TW202033516A (en) |
WO (1) | WO2020104456A1 (en) |
Family Cites Families (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US951A (en) | 1838-09-27 | Improvement in the mode of extracting color from dye-woods | ||
US6358A (en) | 1849-04-17 | Grate for coal-stoves | ||
US2263702A (en) | 1939-01-18 | 1941-11-25 | Konstruktion Und Verwertung Au | Centrifugal clutch construction |
US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
JPS608117B2 (en) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | New physiologically active substance esterastin and its production method |
DE2719912C3 (en) | 1977-05-04 | 1979-12-06 | Bayer Ag, 5090 Leverkusen | Process for the isolation of 0- | 4,6-dideoxy-4- [JJl SO, 4,6 / 5) -4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a - D-glucopyranosyl} - (I right arrow 4) -0- a D-glucopyranosyl- (l right arrow 4) -D-glucopyranose from culture broths |
NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
JPS5953920B2 (en) | 1977-12-28 | 1984-12-27 | 東洋醸造株式会社 | Novel amino sugar compound and its production method |
CA1121290A (en) | 1978-02-14 | 1982-04-06 | Yasuji Suhara | Amino sugar derivatives |
DE2928485A1 (en) | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
ES505959A0 (en) | 1980-10-09 | 1982-09-01 | Hoechst Ag | PROCEDURE FOR THE PREPARATION OF AN ALPHA-AMYLASE INACTIVATOR |
EP0056194B1 (en) | 1981-01-05 | 1984-09-12 | Takeda Chemical Industries, Ltd. | N-substituted pseudo-aminosugars, their production and use |
ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
US4577376A (en) | 1982-01-01 | 1986-03-25 | Clendinen Charles D | Snap fastener |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
FR2549984B1 (en) | 1983-07-29 | 1985-10-18 | Telediffusion Fse | CORRECTION SYSTEM FOR ERRORS OF DIGITAL SIGNALS CODED IN REED-SOLOMON CODE |
DK520784A (en) | 1984-01-21 | 1985-07-22 | Hoechst Ag | CYCLIC POLYPEPTIDES, THEIR PREPARATION AND USE |
US4634765A (en) | 1984-12-18 | 1987-01-06 | Merrell Dow Pharmaceuticals Inc. | Homodisaccharide hypoglycemic agents |
US4751237A (en) | 1986-01-27 | 1988-06-14 | Merck & Co., Inc. | Antihypercholesterolemic beta-lactones |
US4847271A (en) | 1986-01-27 | 1989-07-11 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
US4816477A (en) | 1987-05-26 | 1989-03-28 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
US4806564A (en) | 1987-05-26 | 1989-02-21 | Merck & Co., Inc. | Antihypercholesterolemic beta-lactones |
NZ227042A (en) | 1987-11-27 | 1991-05-28 | Banyu Pharma Co Ltd | Substituted alkylamine derivatives and pharmaceutical compositions |
US5192772A (en) | 1987-12-09 | 1993-03-09 | Nippon Shinyaku Co. Ltd. | Therapeutic agents |
US4919602A (en) | 1987-12-21 | 1990-04-24 | Janszen Arthur W | Apparatus for repairing windshields |
EP0344383A1 (en) | 1988-06-02 | 1989-12-06 | Merrell Dow Pharmaceuticals Inc. | Novel alpha-Glucosidase inhibitors |
DE3836675A1 (en) | 1988-10-28 | 1990-05-03 | Hoechst Ag | GLYCOSIDASE INHIBITOR SALBOSTATIN, PROCESS FOR ITS PREPARATION AND ITS USE |
IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
JPH02169571A (en) | 1988-12-22 | 1990-06-29 | Banyu Pharmaceut Co Ltd | Substituted allylamine derivative |
US5064856A (en) | 1989-07-31 | 1991-11-12 | Merck & Co., Inc. | Novel hmg-coa synthase inhibitors |
US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5504078A (en) | 1990-06-08 | 1996-04-02 | Merrell Dow Pharmaceuticals Inc. | α-glucosidase inhibitors |
US5217877A (en) | 1990-09-28 | 1993-06-08 | Bristol-Myers Squibb Company | Process for the preparation of α-glucosidase inhibitor, pradimicin Q |
US5091418A (en) | 1990-09-28 | 1992-02-25 | Bristol-Myers Squibb Company | Novel alpha-glucosidase inhibitor, pradimicin Q |
US5182298A (en) | 1991-03-18 | 1993-01-26 | Merck & Co., Inc. | Cholesterol lowering agents |
FR2692575B1 (en) | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
FR2714057B1 (en) | 1993-12-17 | 1996-03-08 | Sanofi Elf | New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them. |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
SK57097A3 (en) | 1994-11-07 | 1998-10-07 | Pfizer | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
JPH11501297A (en) | 1995-01-31 | 1999-02-02 | イーライ・リリー・アンド・カンパニー | Anti-obesity protein |
US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
EP0725078A1 (en) | 1995-01-31 | 1996-08-07 | Eli Lilly And Company | Anti-obesity proteins |
US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
FR2741621B1 (en) | 1995-11-23 | 1998-02-13 | Sanofi Sa | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
AU7692696A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
JP2002503202A (en) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | Antidiabetic drugs |
JP2002503203A (en) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | Heterocyclic derivatives as antidiabetic and antiobesity agents |
WO1997027847A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
AU719146B2 (en) | 1996-02-02 | 2000-05-04 | Merck & Co., Inc. | Antidiabetic agents |
CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
IT1288388B1 (en) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | USE OF SUBSTANCES THAT ACTIVATE THE CNTF RECEPTOR (NEUROTROPHIC CHILI FACTOR) FOR THE PREPARATION OF DRUGS FOR THERAPY |
EP0945440B1 (en) | 1996-12-16 | 2004-05-26 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
JPH10237049A (en) | 1996-12-24 | 1998-09-08 | Nippon Chemiphar Co Ltd | Benzisoxazole derivative |
DK1629849T4 (en) | 1997-01-07 | 2017-12-04 | Amylin Pharmaceuticals Llc | Pharmaceutical compositions comprising exedins and agonists thereof |
WO1998031227A1 (en) | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
WO1998033765A1 (en) | 1997-02-04 | 1998-08-06 | E.I. Du Pont De Nemours And Company | Fungicidal carboxamides |
TR199902012T2 (en) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
FR2761265B1 (en) | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3-PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
FR2761266B1 (en) | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
DE69812096T2 (en) | 1997-04-23 | 2003-10-30 | Banyu Pharma Co Ltd | NEUROPEPTID Y RECEPTOR ANTAGONISTS |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
SE9702457D0 (en) | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | screening |
AU8127998A (en) | 1997-07-11 | 1999-02-08 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
EP1032587B2 (en) | 1997-11-14 | 2013-03-13 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
JP2002510688A (en) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | Aminoalkyl-substituted 9H-pyridino [2,3-b] indole and 9H-pyrimidino [4,5-b] indole derivatives |
TR200100137T2 (en) | 1998-04-29 | 2001-05-21 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
JP2002517444A (en) | 1998-06-11 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | Spiropiperidine derivatives as melanocortin receptor agonists |
ATE254382T1 (en) | 1998-07-29 | 2003-11-15 | New Transducers Ltd | SPEAKER DRIVE UNIT HAVING A RESONANT PLATE-SHAPED ELEMENT |
DE19837627A1 (en) | 1998-08-19 | 2000-02-24 | Bayer Ag | New aminoacid esters of arylsulfonamides are useful for e.g. treating neurodegenerative diseases, pain, convulsions or bacterial or viral infections |
HN1998000027A (en) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arylsulphonamides and analogues |
US7358254B2 (en) * | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
EP1121111B1 (en) | 1998-10-15 | 2010-02-10 | Imperial Innovations Limited | Compounds for the treatment of weight loss |
DE69929235T2 (en) | 1998-11-10 | 2006-08-24 | Merck & Co., Inc. | SPIRO INDOLE AS Y5 RECEPTOR ANTAGONISTS |
ES2161594B1 (en) | 1998-12-17 | 2003-04-01 | Servier Lab | NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6344481B1 (en) | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
BR0009026A (en) | 1999-03-19 | 2003-03-05 | Knoll Gmbh | Eating Disorder Treatment Method |
FR2792314B1 (en) | 1999-04-15 | 2001-06-01 | Adir | NOVEL AMINOTRIAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
CA2371274A1 (en) | 1999-04-22 | 2000-11-02 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
CA2373035A1 (en) | 1999-05-05 | 2000-11-16 | Scott Dax | 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders |
US6291476B1 (en) | 1999-05-12 | 2001-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
ES2250126T3 (en) | 1999-06-30 | 2006-04-16 | H. Lundbeck A/S | SELECTIVE ANTAGONISTS OF NPY (Y5). |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
AU783223B2 (en) | 1999-07-28 | 2005-10-06 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
JP2003510327A (en) | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | Heterocycle substituted with specific alkylenediamine |
DE60032249T2 (en) | 1999-09-30 | 2007-07-19 | Neurogen Corp., Branford | Amino-substituted pyrazolo [1,5-a] -1,5-pyrimidines and pyrazolo [1,5-a] -1,3,5-triazines |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
DE19949319A1 (en) | 1999-10-13 | 2001-06-13 | Ruetgers Vft Ag | Process for the preparation of aryl alkyl ethers |
NZ517696A (en) | 1999-10-13 | 2004-12-24 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
ATE303364T1 (en) | 1999-12-16 | 2005-09-15 | Schering Corp | SUBSTITUTED IMIDAZOLES AS NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS |
WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
GB0004003D0 (en) | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
ES2236178T3 (en) | 2000-02-22 | 2005-07-16 | Banyu Pharmaceutical Co., Ltd. | NEW IMIDAZOLINE COMPOUNDS. |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
FR2805810B1 (en) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION |
FR2805818B1 (en) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2805817B1 (en) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
DE60108236T2 (en) | 2000-03-14 | 2005-12-22 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline DERIVATIVES |
US6472398B1 (en) | 2000-03-23 | 2002-10-29 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
JP2003528088A (en) | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | Substituted piperidines as melanocortin receptor agonists |
US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
DK1285651T3 (en) | 2000-04-28 | 2010-12-13 | Takeda Pharmaceutical | Melanin-concentrating hormone antagonists |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
AU2001263021A1 (en) | 2000-05-10 | 2001-11-20 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
EP1286697A2 (en) | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
SE0001899D0 (en) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
JP2003534377A (en) | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | Melanocortin receptor agonist |
WO2001094300A1 (en) | 2000-06-09 | 2001-12-13 | Aventis Pharma Deutschland Gmbh | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
JP2004504303A (en) | 2000-07-05 | 2004-02-12 | シナプティック・ファーマスーティカル・コーポレーション | Selective melanin-concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
MXPA03000738A (en) | 2000-07-24 | 2003-06-04 | Ardana Bioscience Ltd | Ghrelin antagonists. |
JP4180365B2 (en) | 2000-07-31 | 2008-11-12 | エフ.ホフマン−ラ ロシュ アーゲー | Piperazine derivatives |
US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
US6787552B2 (en) | 2000-08-11 | 2004-09-07 | Nippon Chemiphar Co., Ltd. | PPAR delta activators |
AU2001288294A1 (en) | 2000-08-21 | 2002-03-04 | Merck And Co., Inc. | Anti-hypercholesterolemic drug combination |
AU2001283573A1 (en) | 2000-08-21 | 2002-03-04 | Gliatech, Inc. | The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity |
CA2419310A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
CA2422013A1 (en) | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
WO2002026707A1 (en) | 2000-09-26 | 2002-04-04 | Biovitrum Ab | Novel compounds |
WO2002026743A1 (en) | 2000-09-26 | 2002-04-04 | Biovitrum Ab | Novel pyridazine compounds for the treatment of diabetes |
JP2002114768A (en) | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2-(2,5-dihalogen-3,4-dihyroxyphenyl)azole and medicinal composition containing the same |
DZ3482A1 (en) | 2000-10-13 | 2002-04-25 | Lilly Co Eli | SECRETAGOGUES OF THE GROWTH HORMONE |
AU2002221670B2 (en) | 2000-10-16 | 2006-11-02 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-HT2 receptor ligands |
IL154911A0 (en) | 2000-10-20 | 2003-10-31 | Pfizer Prod Inc | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
AU2002227170A1 (en) | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
JP4204315B2 (en) | 2000-11-20 | 2009-01-07 | ビオヴィトルム・アクチボラゲット(プブリクト) | Piperazinyl pyrazine compounds as antagonists of serotonin 5-HT2 receptors |
AU2426602A (en) | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
KR100545431B1 (en) | 2000-12-06 | 2006-01-24 | 에프. 호프만-라 로슈 아게 | Fused heteroaromatic glucokinase activators |
JP2004520299A (en) | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | Spiro [isobenzofuran-1,4'-piperidin] -3-ones and 3H-spiroisobenzofuran-1,4'-piperidines |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
KR20030061458A (en) | 2000-12-21 | 2003-07-18 | 쉐링 코포레이션 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
HUP0302582A2 (en) | 2000-12-22 | 2003-12-29 | Schering Corp. | Piperidine mch antagonists and their use in the treatment of obesity and pharmaceutical compositions containing them |
KR100539143B1 (en) | 2000-12-27 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
ES2247298T3 (en) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | PIPERAZINE AND PIPERIDINE DERIVATIVES AS AGONISTS OF THE MELANOCORTINE RECEPTOR |
WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
JP2004524297A (en) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | Melanocortin receptor agonist |
MXPA03006918A (en) | 2001-02-02 | 2004-05-24 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds. |
ES2283550T3 (en) | 2001-02-28 | 2007-11-01 | MERCK & CO., INC. | PIPERIDINE DERIVATIVES ACILATED AS ANTAGONIST OF THE RECEIVER OF. |
WO2002068387A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
DE60232238D1 (en) | 2001-02-28 | 2009-06-18 | Merck & Co Inc | ACYLATED PIPERIDINE DERIVATIVES THAN MELANOCORTIN-4-RECEPTOR AGONISTS |
UA74066C2 (en) | 2001-03-22 | 2005-10-17 | Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment | |
AU782148B2 (en) | 2001-03-29 | 2005-07-07 | Molecular Design International, Inc. | Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (en) | 2001-05-15 | 2005-05-06 | Servier Lab | NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
ES2257555T3 (en) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | DIPEPTIDILPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES. |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
US6684968B2 (en) | 2001-06-25 | 2004-02-03 | Kennametal Inc. | Roof bit body and insert assembly |
ES2339813T3 (en) | 2001-06-27 | 2010-05-25 | Glaxosmithkline Llc | FLUOROPIRROLIDINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASAS. |
CN1471538A (en) | 2001-06-27 | 2004-01-28 | 前体生物药物股份有限公司 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
EP1399420B1 (en) | 2001-06-27 | 2007-12-05 | SmithKline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
ES2291477T3 (en) | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | FLUOROPIRROLIDINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA. |
WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003007949A1 (en) | 2001-07-18 | 2003-01-30 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
US6915444B2 (en) | 2001-09-12 | 2005-07-05 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
JP2005514008A (en) | 2001-09-24 | 2005-05-19 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Methods for evaluating neurons in the arcuate nucleus to screen for drugs that alter feeding behavior |
EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
JP2013226269A (en) | 2012-04-26 | 2013-11-07 | Maruhon Industry Co Ltd | Pachinko machine |
CA2959208C (en) * | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
MX2019004321A (en) * | 2016-10-14 | 2019-06-12 | Tes Pharma S R L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase. |
US20190367457A1 (en) * | 2016-12-30 | 2019-12-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
-
2019
- 2019-11-19 CN CN201980088947.3A patent/CN113302189A/en active Pending
- 2019-11-19 JP JP2021527887A patent/JP2022507805A/en active Pending
- 2019-11-19 TW TW108141950A patent/TW202033516A/en unknown
- 2019-11-19 SG SG11202104550WA patent/SG11202104550WA/en unknown
- 2019-11-19 WO PCT/EP2019/081799 patent/WO2020104456A1/en unknown
- 2019-11-19 AR ARP190103396A patent/AR117122A1/en unknown
- 2019-11-19 AU AU2019385644A patent/AU2019385644A1/en active Pending
- 2019-11-19 BR BR112021009589-6A patent/BR112021009589A2/en unknown
- 2019-11-19 KR KR1020217018896A patent/KR20210111248A/en unknown
- 2019-11-19 EP EP19809398.1A patent/EP3883930A1/en active Pending
- 2019-11-19 CA CA3119509A patent/CA3119509A1/en active Pending
- 2019-11-19 MX MX2021005904A patent/MX2021005904A/en unknown
-
2021
- 2021-05-13 IL IL283182A patent/IL283182A/en unknown
- 2021-05-19 US US17/325,068 patent/US20220354848A9/en active Pending
-
2023
- 2023-08-09 US US18/447,130 patent/US20230381177A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020500838A5 (en) | ||
JP2018530559A5 (en) | ||
JP2019537557A5 (en) | ||
JP2016518429A5 (en) | ||
RU2019113066A (en) | ISOXAZOLE ANALOGUES AS FXR AGONISTS AND METHODS OF THEIR APPLICATION | |
HRP20210769T1 (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
RU2019114228A (en) | Α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE INHIBITORS | |
HRP20221437T1 (en) | Glp-1 receptor agonists and uses thereof | |
JP2021512114A5 (en) | ||
JP2019094345A5 (en) | ||
JP2019034943A5 (en) | ||
JP2021508686A5 (en) | ||
HRP20150159T1 (en) | Novel fxr (nr1h4 ) binding and activity modulating compounds | |
RU2017120970A (en) | GALLIC ACID DERIVATIVES AS FXR / TGR5 AGONISTS AND WAYS OF THEIR APPLICATION | |
RU2022108080A (en) | INTEGRIN AVB6 INHIBITORS | |
JP2018515581A5 (en) | ||
JPWO2020061101A5 (en) | ||
JP2007500715A5 (en) | ||
JP2019531320A5 (en) | ||
JP2016535784A5 (en) | ||
JP2017529389A5 (en) | ||
JP2007515432A5 (en) | ||
JP2011513367A5 (en) | ||
CA2593264A1 (en) | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
RU2005125209A (en) | Pyrrolopyridazine derivatives |